Logo image of TERN

TERNS PHARMACEUTICALS INC (TERN) Stock Fundamental Analysis

NASDAQ:TERN - Nasdaq - US8808811074 - Common Stock - Currency: USD

3.815  -0.02 (-0.39%)

Fundamental Rating

3

TERN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for TERN as it has an excellent financial health rating, but there are worries on the profitability. TERN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TERN has reported negative net income.
In the past year TERN has reported a negative cash flow from operations.
In the past 5 years TERN always reported negative net income.
TERN had a negative operating cash flow in each of the past 5 years.
TERN Yearly Net Income VS EBIT VS OCF VS FCFTERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of TERN (-26.64%) is comparable to the rest of the industry.
TERN's Return On Equity of -27.72% is fine compared to the rest of the industry. TERN outperforms 65.64% of its industry peers.
Industry RankSector Rank
ROA -26.64%
ROE -27.72%
ROIC N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
TERN Yearly ROA, ROE, ROICTERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TERN Yearly Profit, Operating, Gross MarginsTERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, TERN has more shares outstanding
The number of shares outstanding for TERN has been increased compared to 5 years ago.
There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TERN Yearly Shares OutstandingTERN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TERN Yearly Total Debt VS Total AssetsTERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TERN has an Altman-Z score of 13.43. This indicates that TERN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 13.43, TERN belongs to the best of the industry, outperforming 89.23% of the companies in the same industry.
TERN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.43
ROIC/WACCN/A
WACCN/A
TERN Yearly LT Debt VS Equity VS FCFTERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 30.89 indicates that TERN has no problem at all paying its short term obligations.
TERN has a better Current ratio (30.89) than 97.44% of its industry peers.
TERN has a Quick Ratio of 30.89. This indicates that TERN is financially healthy and has no problem in meeting its short term obligations.
TERN's Quick ratio of 30.89 is amongst the best of the industry. TERN outperforms 97.44% of its industry peers.
Industry RankSector Rank
Current Ratio 30.89
Quick Ratio 30.89
TERN Yearly Current Assets VS Current LiabilitesTERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.49% over the past year.
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TERN will show a small growth in Earnings Per Share. The EPS will grow by 4.27% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.54%
EPS Next 2Y-9.66%
EPS Next 3Y-11.65%
EPS Next 5Y4.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TERN Yearly Revenue VS EstimatesTERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 100M 200M 300M 400M
TERN Yearly EPS VS EstimatesTERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TERN. In the last year negative earnings were reported.
Also next year TERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TERN Price Earnings VS Forward Price EarningsTERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TERN Per share dataTERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as TERN's earnings are expected to decrease with -11.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.66%
EPS Next 3Y-11.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TERN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (6/30/2025, 3:00:53 PM)

3.815

-0.02 (-0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners91.42%
Inst Owner Change2.02%
Ins Owners0.22%
Ins Owner Change3.26%
Market Cap333.20M
Analysts80
Price Target18.58 (387.02%)
Short Float %6.84%
Short Ratio5.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.52%
Min EPS beat(2)8.96%
Max EPS beat(2)24.07%
EPS beat(4)4
Avg EPS beat(4)14.49%
Min EPS beat(4)8.96%
Max EPS beat(4)24.07%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)10
Avg EPS beat(12)9.41%
EPS beat(16)14
Avg EPS beat(16)12.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.94%
PT rev (3m)-8.6%
EPS NQ rev (1m)-1.97%
EPS NQ rev (3m)11.06%
EPS NY rev (1m)2.85%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0
BVpS3.73
TBVpS3.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.64%
ROE -27.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 30.89
Quick Ratio 30.89
Altman-Z 13.43
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)22.97%
Cap/Depr(5y)56.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y-7.54%
EPS Next 2Y-9.66%
EPS Next 3Y-11.65%
EPS Next 5Y4.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.94%
EBIT Next 3Y-18.04%
EBIT Next 5Y1.17%
FCF growth 1Y-42.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.77%
OCF growth 3YN/A
OCF growth 5YN/A